Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Truscreen GroupASX:TRU Equity-to-Asset is 0.69 as of Mar. 2026, which is 16% below its 10-year median of 0.82. The stock has 4 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Truscreen Group ranks better than 58.64% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Truscreen Group's Total Stockholders Equity for the quarter that ended in Mar. 2026 was A$2.15 Mil. Truscreen Group's Total Assets for the quarter that ended in Mar. 2026 was A$3.12 Mil.
The historical rank and industry rank for Truscreen Group's Equity-to-Asset or its related term are showing as below:
ASX:TRU'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.55 Med: 0.82 Max: 0.95
Current: 0.69
During the past 12 years, the highest Equity to Asset Ratio of Truscreen Group was 0.95. The lowest was 0.55. And the median was 0.82.
ASX:TRU's Equity-to-Asset is ranked better than 58.64% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs ASX:TRU: 0.69
Truscreen Group (ASX:TRU) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Truscreen Group Equity-to-Asset Related Terms
Truscreen Group Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Truscreen Group's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:TRU vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Truscreen Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Truscreen Group Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Truscreen Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Truscreen Group's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Truscreen Group's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Truscreen Group (ASX:TRU) has a Equity-to-Asset of 0.69 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Truscreen Group and its competitors. This is 16% below median its historical median of 0.82. Over the past decade, Truscreen Group's Equity-to-Asset has ranged from 0.55 to 0.95. According to the industry distribution chart, Truscreen Group ranks #352 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 41.4%.
Is Truscreen Group's Equity-to-Asset too high?
Truscreen Group's current Equity-to-Asset of 0.69 is 16% below median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 0.95. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Truscreen Group's value of 0.69 is 7.8% above this industry median. Based on the distribution chart, Truscreen Group ranks #352 out of 851 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Truscreen Group's Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Truscreen Group ranks #352 out of 851 companies for Equity-to-Asset. This puts Truscreen Group in the upper half of its industry. The industry median Equity-to-Asset is 0.64. Truscreen Group's value of 0.69 is 7.8% above this benchmark. Historically, Truscreen Group's own Equity-to-Asset has ranged from 0.55 to 0.95 over the past decade. While the company's 10-year median is 0.82 vs. the industry median of 0.64, Truscreen Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Truscreen Group's current Equity-to-Asset of 0.69 is 7.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Truscreen Group and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Truscreen Group's current Equity-to-Asset is 0.69, which is 16% below median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Truscreen Group stock overvalued right now?
Based on GuruFocus' analysis, Truscreen Group (ASX:TRU) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading 20% above its estimated fair value. The current Equity-to-Asset is 0.69, which is 16% below median its 10-year median of 0.82 and 7.8% above the Medical Devices & Instruments industry median of 0.64. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Truscreen Group (ASX:TRU), the current Equity-to-Asset is 0.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Truscreen Group Ltd is a medical device company. The company manufactures and distributes the Truscreen Cervical Cancer screening device, which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. The product utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. Geographically, the company operates its business in New Zealand, Mexico, China, Russia, Zimbabwe, Vietnam, and other countries. Maximum revenue is generated from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TRU has been successfully added to your 
